Design of sustained release tablet containing fucoidan.
The study introduced a new therapeutic agent, fucoidan, which can offer potential medical treatments including anti-inflammatory and anti-coagulant activities, as well as anti-proliferative effects on cancer cells. Fucoidan was included in sustained release formulations expected for an effective plasma drug concentration for approximately 24 h. The matrices based on the two polymers hydroxypropyl methycellulose (HPMC) and polyethylene oxide (PEO) were prepared with various ratios between the polymers and fucoidan. The dissolution profiles of various matrix tablets performed in enzyme-free simulated intestinal fluid (pH 6.8) for 24 h indicated a higher potential of PEO-based matrix tablets in sustaining release of fucoidan. The swelling and erosion of the tablets were also characterized to elucidate the difference among those dissolution profiles.
Thao Truong-Dinh
TT
Tran
Dai Kieu-Phuong
DK
Ngo
Toi Van
TV
Vo
Phuong Ha-Lien
PH
Tran
D003692:Delayed-Action Preparations / Q000737:chemistry*; D015195:Drug Design; D065546:Drug Liberation; D065347:Hypromellose Derivatives / Q000737:chemistry; D011092:Polyethylene Glycols / Q000737:chemistry; D011134:Polysaccharides / Q000737:chemistry*; D013607:Tablets
D003692:Delayed-Action Preparations; D011134:Polysaccharides; D013607:Tablets; D065347:Hypromellose Derivatives; D011092:Polyethylene Glycols; C007789:fucoidan